Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. - Wikidata - wikimedia - TriplyDB

Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.

Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.

http://www.wikidata.org/entity/Q39557682

about

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins Methodologies for the isolation of alternative binders with improved clinical potentiality over conventional antibodies.The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression.A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.Fc-fusion proteins: new developments and future perspectives.Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.Nanotechnology for protein delivery: Overview and perspectives.Affinity improvement of a therapeutic antibody by structure-based computational design: generation of electrostatic interactions in the transition state stabilizes the antibody-antigen complex.The making of bispecific antibodies Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies.Generation of human bispecific common light chain antibodies by combining animal immunization and yeast display.

P2860

Q27679191-0319B046-9448-4B04-83AB-6D2E82AEC35B Q28072319-391B9BEB-FB9D-4D68-9709-84FD7041790D Q34220190-517568B2-FD48-4ECC-8CA9-7EB9EB83B314 Q35037251-6394BAA4-9755-4C58-BBB6-AA88631137A2 Q37593702-41A1275A-94EE-42E4-81F1-90C056E7A2E8 Q38029985-7358BA06-3A98-4EA1-BC87-698FB9C9309A Q38038410-51F0CFB3-3635-43CF-8E9D-A3EA80F0F2C2 Q38605185-38534F17-5624-4E91-B438-FB3940B9F36D Q41894132-25236E68-AF0E-436E-8BA5-E35D93637E43 Q42323236-605C80DE-8322-4D91-90EF-97AC5AA36C31 Q42499937-BDA06E58-F789-476A-BF32-53934D22958A Q47597795-2D19CD1C-BAAF-4380-93AA-B5209DFD8EFD Q48877236-4A37C046-A055-404E-8F7D-0CFE7E72637C

P2860

Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.

http://www.wikidata.org/entity/Q39557682

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Therapeutic assessment of SEED ...... no- and bispecific antibodies.

@en

Therapeutic assessment of SEED ...... no- and bispecific antibodies.

@nl

type

label

Therapeutic assessment of SEED ...... no- and bispecific antibodies.

@en

Therapeutic assessment of SEED ...... no- and bispecific antibodies.

@nl

prefLabel

Therapeutic assessment of SEED ...... no- and bispecific antibodies.

@en

Therapeutic assessment of SEED ...... no- and bispecific antibodies.

@nl

P1433

Q39557682-A89B3CF6-5E54-4E4C-9644-0470D9E0DE64

P1476

Q39557682-4134A6FE-06BF-4867-AF2B-BF91D8208BE6

P2093

Q39557682-00E0DD49-1533-4890-A54D-E81BA48AAAC4

Q39557682-407A00E0-A64A-4D00-97B9-69541EAEBED1

Q39557682-427256B7-4994-46F9-B6C3-9FCA329FB7A3

Q39557682-43741565-C7D2-41E2-9483-CC06E243087E

Q39557682-48729EB7-69E1-468C-9BFE-CC278132ECD7

Q39557682-4C56ED95-2989-4372-AB13-2BACD51A0128

Q39557682-6F5B5C9D-3A9B-464B-A259-37E22AF419F8

Q39557682-9229924C-4964-4DEB-B370-52856188734D

Q39557682-AF828696-E79F-479F-9567-F28EA08F95ED

Q39557682-B2E14B4F-2D69-4B11-B568-E7E9DF6E8827

P2860

Q39557682-085AA94E-6865-4152-83A6-41FC5E02D426

Q39557682-1DCBA6A3-847F-4CDD-A3F3-15E8DEF0D906

Q39557682-267C9644-30C0-4038-89FF-DC9A1C97994B

Q39557682-29D2F1CE-CA19-4CDF-A18B-DD307652DD0C

Q39557682-2FF06B02-9CFA-4DC6-9A59-7EF80B2CF004

Q39557682-35AEBB71-D0D1-484E-98D8-C2405108B251

Q39557682-47C53C98-CB32-4539-B7A6-47C86D52B364

Q39557682-4A6C9A56-A421-4E6D-9D4F-1AED08E043F3

Q39557682-5BA01110-2E27-4355-AD09-2492BBBA1735

Q39557682-6542355E-1095-414F-82CB-EC118158E7CC

P304

Q39557682-4C7775BA-0BEA-4CB2-BE87-3C43D4D3ECF5

P31

Q39557682-4731FAA4-0386-44AD-8CD3-421C000CED8E

P356

Q39557682-2940C29A-DAA3-4FD2-96E3-FD10A5A22F1B

P433

Q39557682-478E4028-8772-42A2-A869-0C4BADCEB058

P478

Q39557682-567BB29C-3DA2-44B3-9A22-0E8A7D537CE5

P577

Q39557682-D909078F-AC6C-4145-A8EC-910FDAB2CF40

P5875

Q39557682-68F24680-F73D-4012-B70C-427640973DC8

P698

Q39557682-3C89F846-CD54-4664-B5CD-3E5C582FBC2E

P921

Q39557682-ADD1F1B7-38CD-4B8E-9442-D382EFE55970

P356

P1433

Protein Engineering Design and Selection

P1476

Therapeutic assessment of SEED ...... no- and bispecific antibodies.

@en

P2093

Alec W Gross

http://www.w3.org/2001/XMLSchema#string

Anna Bernhardt

http://www.w3.org/2001/XMLSchema#string

Berend Neuteboom

http://www.w3.org/2001/XMLSchema#string

Bjoern Hock

http://www.w3.org/2001/XMLSchema#string

Chaomei He

http://www.w3.org/2001/XMLSchema#string

Christie Kelton

http://www.w3.org/2001/XMLSchema#string

David Fischer

http://www.w3.org/2001/XMLSchema#string

Emmi Kurosawa

http://www.w3.org/2001/XMLSchema#string

Jessica P Dawson

http://www.w3.org/2001/XMLSchema#string

John S Wesolowski

http://www.w3.org/2001/XMLSchema#string

P2860

The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein

High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

Bispecific antibodies for cancer immunotherapy: Current perspectives

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

An efficient route to human bispecific IgG.

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

P304

447-454

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/PROTEIN/GZQ123

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51056432

http://www.w3.org/2001/XMLSchema#string

P698

21498564

http://www.w3.org/2001/XMLSchema#string

P921